Literature DB >> 7527333

Expression of insulin-like growth factors and their binding proteins in the estrogen responsive Ishikawa human endometrial cancer cell line.

V Hana1, L J Murphy.   

Abstract

In uterine tissue, estrogen regulates various components of the insulin-like growth factor system; however, there are few suitable in vitro systems to examine these effects. Here we have examined the effects of 17-beta estradiol (E2) on expression and synthesis of insulin-like growth factors (IGF-I and IGF-II) and the insulin-like growth factor binding proteins (IGFBPs) by Ishikawa human endometrial cancer cells. Using a semiquantitative reverse transcription-polymerase chain reaction (RT-PCR) assay, we demonstrated that both E2 and 4-hydroxy-tamoxifen (OHT) enhanced IGF-I expression but had no effect on IGF-II expression. The pure antiestrogen ICI 182,780 had no effect on IGF-I expression and partially blocked the E2 and OHT effect on IGF-I expression. The effect of epidermal growth factor (EGF), which is able to mimic some of the effects of E2 in Ishikawa cells and uterine tissue, was also examined. EGF, unlike E2, did not increase IGF-I expression but rather resulted in a significant decrease in IGF-I messenger RNA (mRNA) levels. EGF also resulted in a small, nonsignificant increase in IGF-II mRNA levels. IGFBP-3, -5, and -6 mRNAs were detected by Northern blot analyses of Ishikawa cells RNA. However, only IGFBP-3 was consistently detected by ligand blotting of conditioned medium. E2 had no significant effect on expression of any of the binding proteins, whereas EGF increased IGFBP-5 mRNA levels. These data provide the first in vitro demonstration of regulation of IGF-I expression by E2. The Ishikawa cell line may provide a useful model to further investigate the molecular mechanisms underlying E2 regulation of IGF-I expression. Furthermore, we have demonstrated a clear dissociation of the effects of E2 and EGF on IGF-I expression in this cell line.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7527333     DOI: 10.1210/endo.135.6.7527333

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  5 in total

1.  The effect of IGF-I receptor blockade for human esophageal squamous cell carcinoma and adenocarcinoma.

Authors:  Yasushi Adachi; Hirokazu Ohashi; Arisa Imsumran; Hiroyuki Yamamoto; Yasutaka Matsunaga; Hiroaki Taniguchi; Katsuhiko Nosho; Hiromu Suzuki; Yasushi Sasaki; Yoshiaki Arimura; David P Carbone; Kohzoh Imai; Yasuhisa Shinomura
Journal:  Tumour Biol       Date:  2013-09-13

2.  Endometrial Cancer Insulin-Like Growth Factor 1 Receptor (IGF1R) Expression Increases with Body Mass Index and Is Associated with Pathologic Extent and Prognosis.

Authors:  Amy S Joehlin-Price; Julie A Stephens; Jianying Zhang; Floor J Backes; David E Cohn; Adrian A Suarez
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-12-18       Impact factor: 4.254

3.  Insulin-like growth factor I receptor blockade enhances chemotherapy and radiation responses and inhibits tumour growth in human gastric cancer xenografts.

Authors:  Y Min; Y Adachi; H Yamamoto; A Imsumran; Y Arimura; T Endo; Y Hinoda; C-T Lee; S Nadaf; D P Carbone; K Imai
Journal:  Gut       Date:  2005-05       Impact factor: 23.059

4.  In vitro and in vivo effects of the PPAR-alpha agonists fenofibrate and retinoic acid in endometrial cancer.

Authors:  Samir A Saidi; Cathrine M Holland; D Stephen Charnock-Jones; Stephen K Smith
Journal:  Mol Cancer       Date:  2006-03-28       Impact factor: 27.401

Review 5.  Endometrial Cancer as a Metabolic Disease with Dysregulated PI3K Signaling: Shedding Light on Novel Therapeutic Strategies.

Authors:  Satoru Kyo; Kentaro Nakayama
Journal:  Int J Mol Sci       Date:  2020-08-23       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.